Inclusion Criteria:  Able and willing to provide informed consent Postmenopausal women (FSH ≥ 16 IU/L) (no menses for at least one year) Aged 50-75 years  Exclusion Criteria:  Clinical diagnosis of diabetes mellitus requiring insulin Clinically significant abnormality in any of the additional screening laboratory studies A1c- ≥8 Calcium - > upper limit lab value per site AST- 2x upper normal limit FSH- < 16IU/L eGFR- < 45 mL/min/1.73m2 based on creatinine CBC- Per PI interpretation of each patient  Presence of (documented clinical diagnosis of any of the following):  Significant liver or renal disease Malignancy (including myeloma or clinical diagnosis of MGUS) Malabsorption (as defined by clinical diagnosis) Hypoparathyroidism (as defined by clinical diagnosis) Hyperparathyroidism (as defined by clinical diagnosis) Acromegaly Cushing syndrome Hypopituitarism Severe chronic obstructive pulmonary disease Pheochromocytoma History of cardiac failure Ejection Fraction <35% PR interval > 200 msec on screening ECG or known heart block History of bronchospastic disease Gastric Bypass Parkinson's Rheumatoid Arthritis Psoriatic Arthritis Connective Tissue disease  Undergoing treatment with any medications that affect bone turnover, including the following:  adrenocorticosteroids (oral for > 3 months within the past year or sustained inhaled corticosteroid use) anticonvulsant therapy for seizures (carbamazepine, phenobarbital, or phenytoin within the previous year) pharmacological doses of: thyroid hormone (causing decline of thyroid stimulating hormone below normal, i.e. < 0.3 miU/L) bisphosphonates (within the past 3 yrs) denosumab, romosozumab, estrogen therapy or treatment with a selective estrogen receptor modulator, or teriparatide/abaloparatide (within the past year) Current use of calcium channel blockers Current use of digitalis glycosides Current or within the past 3 months use of thiazide diuretics Current or within the past 3 months use of beta blockers Clinical history of osteoporotic fracture (vertebral, hip, distal forearm, humerus, or pelvis), or any recent fracture within the past 6 months prior to screening (other than fingers, toes and facial fractures, which are all acceptable) Evidence of moderate/severe vertebral deformity based on DXA vertebral fracture assessment at screening Spine or femur neck T-score ≤ -2.5, or 1/3 radius T-score ≤ -3, as they may be candidates for standard osteoporosis drugs Patients with serum 25-hydroxyvitamin D levels of < 20 ng/ml, in order to ensure vitamin D sufficiency Resting systolic blood pressure < 120 mm Hg, heart rate < 55 bpm (average of 3 readings after a 5-minute rest and one minute between readings with an automatic cuff)